FDA's AI in Early Phase Clinical Trials RFI: An Opportunity to Help Set the Rules of the Road
PushButton AI Team ·
FDA's AI in Early Phase Clinical Trials RFI: An Opportunity to Help Set the Rules of the Road
Even the FDA is now figuring out AI rules in real time.
That should tell you something important.
If you bought an AI tool that nobody on your team actually uses, you're not behind. You're actually
Even the FDA is now figuring out AI rules in real time.
That should tell you something important.
If you bought an AI tool that nobody on your team actually uses, you're not behind. You're actually right where most businesses are — including highly regulated industries that move slowly and carefully.
The shame of that unused subscription isn't a failure of intelligence. It's a failure of implementation sequencing. You got handed a hammer before anyone agreed what needed building.
Here's what the FDA story reveals that applies directly to you:
The organizations getting ahead with AI aren't the ones who bought the most tools. They're the ones who identified one specific problem first, then found the tool that fits. That order matters enormously.
Regulators are learning alongside everyone else. Which means the window to become the AI-savvy leader in your industry is still wide open.
One thing you can do this week: Write down the single most repetitive task your team complains about. That's your starting point — not a platform demo, not a consultant pitch. Just that one task.
That list of one becomes your AI roadmap.
What's the AI tool you bought that nobody ended up using — and what did you hope it would actually solve?
This can be especially challenging for small biotech and early-stage companies. 2. Earlier FDA collaboration could become a competitive advantage — ...
